• Ischemic Stroke
    • Tae Jung Kim
    • Tae Jung Kim: Influence Statistics

      Tae Jung Kim

      Tae Jung Kim

      Show email address

      Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. | Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Tae Jung Kim:Expert Impact

      Concepts for whichTae Jung Kimhas direct influence:Ischemic stroke,Lung cancer,Alk rearrangement,Elderly patients,Early neurological deterioration,Lung adenocarcinoma,Active cancer,Esophageal cancer.

      Tae Jung Kim:KOL impact

      Concepts related to the work of other authors for whichfor which Tae Jung Kim has influence:Lung cancer,Ischemic stroke,Intracerebral hemorrhage,Computed tomography,Pulmonary nodules,Magnetic resonance,Egfr mutations.

      KOL Resume for Tae Jung Kim


      Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.


      Department of Radiology, The University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

      Seoul National University College of Medicine, Seoul, Korea


      Department of Critical Care Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea


      Department of Hospital Pathology, Yeouido St. Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.


      Department of Hospital Pathology, The Catholic University of Korea College of Medicine, Seoul, Korea.

      Seoul National University Hospital, Korea (K.-W.N., T.J.K., S.-B.K., B.-W.Y.).


      Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.


      Department of Bioengineering University of Pittsburgh Pittsburgh Pennsylvania USA

      Samsung Med. Center, South Korea

      The first two authors contributed equally to this article.


      Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

      Biomedical Research Institute, Seoul National University Hospital, 03080, Seoul, Republic of Korea


      Department of Pathology, The Catholic University of Korea College of Medicine, Seoul, Korea.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Tae Jung Kim is among the top experts in the world.
      Concept World rank
      894 100g #1
      alk driver #1
      percentage solid component #1
      total 475 cases #1
      highest quintile level #1
      surepath thyroid fnac #1
      histopathologic diagnosis core #1
      3278 years #1
      media asbestos #1
      glut expression #1
      asbestos microenvironment #1
      asl mb #1
      pathognomic cells #1
      ambiguous alk test #1
      features spread #1
      individual pathological analysis #1
      cbf normotensives #1
      unequal samplesplitting #1
      radiogenomic correlation #1
      media lung fibroblasts #1
      copd lower prevalences #1
      egfr lesion margin #1
      specimens cin1 #1
      100 labor time #1
      alk driver mutations #1
      hpv16positive cervical cytology #1
      highest quintile ces #1
      diagnostic utility surepath #1
      histologic features ppfe #1
      egfr lesion #1
      fralpha hent1 #1
      igf1r expression response #1
      negative egfr mutation #1
      cores adequate #1
      solitary ground #1
      cin2 hpv l1 #1
      air bronchogram percentage #1
      features percentage #1
      4th needle #1
      alk 318 #1
      air bronchogram stas #1
      patients persistent ascus #1
      reviewed thick #1
      lesion margin alk #1
      475 cases #1
      immunocytochemistry hpv #1
      wt wt alk #1
      asbestosexposed lung fibroblasts #1
      lsil ≥ #1
      tumours egfr mutation #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Tae Jung Kim

      KOL-Index: 18986

      BACKGROUND: Mutations in the TERT promoter, ALK rearrangement, and the BRAF V600E mutation are associated with aggressive clinicopathologic features in thyroid cancers. However, little is known about the impact of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of BRAF mutations.

      METHODS: We performed Sanger sequencing to detect BRAF V600E and TERT promoter mutations and both immunohistochemistry and fluorescence in situ hybridization to ...

      Known for Tert Promoter | V600e Mutation | Distant Metastasis | Clinical Utility | Situ Hybridization
      KOL-Index: 14717

      BACKGROUND: Radiogenomic features are predictive of anaplastic lymphoma kinase (ALK) rearrangement in surgically resected non-small cell lung cancer (NSCLC).

      METHODS: ALK rearrangement was screened by fluorescent in situ hybridization in 497 patients with resected NSCLC. Of these, 198 patients screened for both ALK and epidermal growth factor receptor (EGFR) mutation were enrolled. Clinicopathologic findings, survival after surgical procedure, computed tomographic (CT) features, and ...

      Known for Alk Rearrangement | Egfr Mutations | Lung Cancer | Small Cell | Surgically Resected
      KOL-Index: 13683

      BACKGROUND: Simultaneous genotyping has advantages in turnaround time and detecting the real mutational prevalence in unresectable non-small-cell lung cancer (NSCLC), a group not previously genetically characterized.

      METHODS: We developed simultaneous panel of screening EGFR and KRAS mutations by direct sequencing or PNA clamping, and ALK rearrangement by fluorescent in situ hybridization (FISH) in multicenter manner.

      RESULTS: Of 510 NSCLC Korean patients, simultaneous genotyping ...

      Known for Alk Rearrangement | Cell Lung | Situ Hybridization | Egfr Kras | Anaplastic Lymphoma Kinase
      KOL-Index: 13678

      BACKGROUND: The tyrosine kinase inhibitor imatinib mesylate was developed as an inhibitor of the kinase activity of BCR-ABL. However, imatinib also has potent inhibitory activity against the platelet-derived growth factor receptor (PDGFR). Nilotinib is approved for treating patients with chronic myeloid leukemia showing resistance or intolerance to imatinib. Like imatinib, nilotinib selectively inhibits the tyrosine kinase activity of PDGFR.

      OBJECTIVES: We examined the effect of imatinib ...

      Known for Lung Injury | Imatinib Nilotinib | Pulmonary Fibrosis | Induced Acute | Bleomycin Instillation
      KOL-Index: 12261

      OBJECTIVES: Expression of insulin-like growth factor 1 receptor (IGF-1R) in non-small cell lung cancer (NSCLC) is associated with poor prognosis. The IGF-1R pathway activates downstream targets that bypass dependency in signals from the epidermal growth factor receptor (EGFR), which mediates resistance to EGFR tyrosine kinase inhibitors (TKIs). The aim of the present study was to determine the predictive role of IGF-1R expression in the response to EGFR-TKIs of NSCLC patients harboring ...

      Known for 1 Receptor | Growth Factor | Cell Lung | Egfr Mutations | Tyrosine Kinase
      KOL-Index: 11457

      BACKGROUND: This study analyzed the relation between the tumor size and the lymph node metastasis in adenocarcinoma of the lung with a size of 30 mm or smaller.

      METHODS: Four hundred thirteen patients who had undergone curative resection for lung adenocarcinoma were enrolled. If the tumor presented ground-glass opacities on the preoperative high-resolution computed tomography, both the total size including ground-glass opacities and the solid size alone were measured. To calculate the ...

      Known for Lymph Node Metastasis | Tumor Size | 30 Mm | Lung Adenocarcinoma | Computed Tomography
      KOL-Index: 11260

      Lung cancer and chronic obstructive pulmonary disease (COPD) are two major lung diseases. Epidermal growth factor receptor (EGFR) mutations, v-Ki-ras2 Kirsten rat sarcoma (KRAS) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements represent driver mutations that are frequently assessed on initial evaluation of non-small-cell lung cancer (NSCLC). The present study focused on the expression of driver mutations in NSCLC patients presenting with COPD and further evaluated the ...

      Known for Lung Cancer | Egfr Mutations | Pulmonary Disease | Chronic Obstructive | Nsclc Copd
      KOL-Index: 11059

      Functional magnetic resonance imaging (fMRI) in anesthetized rodents has been commonly performed with alpha-chloralose, which can be used only for terminal experiments. To develop a survival fMRI protocol, an isoflurane (ISO) -anesthetized rat model was systematically evaluated by simultaneous measurements of field potential (FP) and cerebral blood flow (CBF) in the somatosensory cortex. A conventional forepaw stimulation paradigm with 0.3 ms pulse width, 1.2 mA current, and 3 Hz ...

      Known for Somatosensory Cortex | Bold Signals | Anesthetized Rat | Iso Cbf | Stimulation Parameters
      KOL-Index: 11042

      BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.

      METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation. In ...

      Known for Basal Cell Carcinoma | Squamous Cell | Immunohistochemical Markers | Expression Ki67 | Matrix Metalloproteinase
      KOL-Index: 10872

      BACKGROUND: The objective of this study was to investigate the expression of human papilloma virus (HPV) L1 capsid protein in abnormal cervical cytology with HPV16 infection and analyze its association with cervical histopathology in Korean women.

      MATERIAL AND METHODS: We performed immunocytochemistry for HPV L1 in 475 abnormal cervical cytology samples from patients with HPV16 infections using the Cytoactiv(®) HPV L1 screening set. We investigated the expression of HPV L1 in cervical ...

      Known for Hpv L1 | Cervical Cytology | Human Papilloma Virus | Ascus Lsil | Capsid Proteins
      KOL-Index: 10789

      OBJECTIVE: The purposes of our study were to evaluate 18F-FDG PET findings of ground-glass opacity (GGO) nodules and to determine the value of FDG PET for the preoperative staging of lung cancer manifesting predominantly as GGO.

      MATERIALS AND METHODS: Eighty-nine patients (46 men and 43 women; mean [±SD] age, 62.4±7.2 years [range, 33-81 years] and 61.7±6.7 years [range, 34-75 years], respectively) with 134 GGO nodules (56 single and 78 multiple) who underwent CT and FDG PET before ...

      Known for Fdg Pet | Lung Cancer | Lesion Size | Glass Opacity | Ggo Percentage
      KOL-Index: 10647

      1. Pravastatin is best known for its antilipidemic action. Recent studies have shown that statins have immunomodulatory and anti-inflammatory effects. The present study aimed to determine whether or not pravastatin can attenuate acute lung injury and fibrosis in a mouse model. 2. Bleomycin was given to C57BL6 mice through intratracheal instillation. Pravastatin was given through intraperitoneal injection. To study the effect of pravastatin on the early inflammatory phase and the late ...

      Known for Lung Injury | Pulmonary Fibrosis | Intratracheal Instillation | Intraperitoneal Injection | Tissue Growth
      KOL-Index: 10408

      INTRODUCTION: No standard guidelines detailing recommendations for the selection and treatment for multiple lung nodules with ground-glass opacity (GGO) have been established. For treatment decision, we analyzed epidermal growth factor receptor (EGFR)/K-ras somatic aberrations and pathologic-radiologic correlation in multiple lung nodules presented as GGO to differentiate multifocal lesions from intrapulmonary spread.

      METHODS: Twenty-four patients with multiple lung nodules presented as ...

      Known for Multiple Lung | Aah Bac | Glass Opacity | Growth Factor | Receptor Mutation
      KOL-Index: 10345

      Regional cerebral arterial blood volume (CBVa) and blood flow (CBF) can be quantitatively measured by modulation of tissue and vessel (MOTIVE) signals, enabling separation of tissue signal from blood. Tissue signal is selectively modulated using magnetization transfer (MT) effects. Blood signal is changed either by injection of a contrast agent or by arterial spin labeling (ASL). The measured blood volume represents CBVa because the contribution from venous blood was insignificant in our ...

      Known for Blood Flow | Contrast Agent | Cerebral Arterial | Cbva Values | Tissue Signal
      KOL-Index: 10168

      ObjectivesTo correlate imaging features of resected lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and the IASLC/ATS/ERS classification histological subtypes.MethodsIn 250 consecutive patients with resected lung adenocarcinoma, EGFR mutation status was correlated with demographics, imaging features including ground-glass opacity (GGO) proportion and the IASLC/ATS/ERS classification histological subtypes.ResultsEGFR mutations were significantly more frequent in ...

      Known for Lung Adenocarcinoma | Imaging Features | Histological Subtypes | Egfr Mutation | Ggo Proportion

      Key People For Ischemic Stroke

      Top KOLs in the world
      Ralph L Sacco
      ischemic stroke northern manhattan study carotid plaque
      Harold P Jr Adams
      ischemic stroke cerebral infarction subarachnoid hemorrhage
      José Biller
      ischemic stroke cerebral infarction neurologic complications
      Laurens Jaap Kappelle
      ischemic stroke type 2 diabetes cognitive impairment
      Geoffrey Alan Donnan
      ischemic stroke atrial fibrillation intracerebral haemorrhage
      Jeffrey L Saver
      acute ischemic stroke endovascular thrombectomy united states

      Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. | Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. | Department of Radiology, The University of Pittsburgh, Pittsburgh, Penn

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.